Document is current
Any future updates will be listed below
-
Authors
Osugo, Martin https://orcid.org/0000-0002-5462-8464
Zahid, Uzma https://orcid.org/0000-0002-7849-4907
Selvaggi, Pierluigi https://orcid.org/0000-0001-9069-0700
Chilimidos, Alexandria
Finelli, Valeria https://orcid.org/0009-0006-1026-4626
Chapman, George E. https://orcid.org/0000-0001-7874-0314
Whitehurst, Thomas
Onwordi, Ellis Chika
Murray, Robin M. https://orcid.org/0000-0003-0829-0519
Wall, Matthew B.
Marques, Tiago Reis https://orcid.org/0000-0003-0602-7661
Mehta, Mitul A. https://orcid.org/0000-0003-1152-5323
Howes, Oliver D. https://orcid.org/0000-0002-2928-1972
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research
EC | Horizon 2020 Framework Programme (No. 964874 (REALMENT))
RCUK | Medical Research Council (grant no. MC_ U120097115)
- License Information
-
More Information
Article History
Received: 18 December 2024
Revised: 16 June 2025
Accepted: 8 July 2025
First Online: 19 July 2025
Competing interests
: ODH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack/ Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris/ Mylan. He was previously a part-time employee of Lundbeck A/v. Neither ODH nor his family have holdings/a financial stake in any pharmaceutical company. ODH has a patent for the use of dopaminergic imaging. MW is an employee of Perceptive Inc., London. TRM is an employee and have shares of Pasithea Therapeutics. Other authors have reported no biomedical financial interests or potential conflicts of interest.
